Verteporfin-Loaded Anisotropic Poly(Beta-Amino Ester)-Based Micelles Demonstrate Brain Cancer-Selective Cytotoxicity and Enhanced Pharmacokinetics

References

• Davis ME. Glioblastoma: overview of disease and treatment. Clin J Oncol Nurs. 2016;20(5 Suppl):S2–S8.
   PubMed Web of Science ®Google Scholar
• Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352(10):987–996. doi:10.1056/NEJMoa04333015758009
   PubMed Web of Science ®Google Scholar
• Tamimi A, Juweid M. Epidemiology and Outcome of Glioblastoma. Brisbane (AU): Codon Publications; 2017.
   Google Scholar
• Hochberg FH, Pruitt A. Assumptions in the radiotherapy of glioblastoma. Neurology. 1980;30(9):907–911. doi:10.1212/WNL.30.9.9076252514
   PubMed Web of Science ®Google Scholar
• Wen PY, Kesari S. Malignant gliomas in adults. N Engl J Med. 2008;359(5):492–507. doi:10.1056/NEJMra070812618669428
   PubMed Web of Science ®Google Scholar
• Daneman R, Prat A. The blood-brain barrier. Cold Spring Harb Perspect Biol. 2015;7(1):a020412. doi:10.1101/cshperspect.a02041225561720
   PubMed Web of Science ®Google Scholar
• Wei S, Wang J, Oyinlade O, et al. Heterozygous IDH1(R132H/WT) created by “single base editing” inhibits human astroglial cell growth by downregulating YAP. Oncogene. 2018;37(38):5160–5174. doi:10.1038/s41388-018-0334-929849122
   PubMedGoogle Scholar
• Shah SR, Quinones-Hinojosa A, Xia S. Advances in brain cancer: creating monoallelic single point mutation in IDH1 by single base editing. J Oncol Res Ther. 2019;5(5):166.31328182
   PubMedGoogle Scholar
• Xiao W, Sohrabi A, Seidlits SK. Integrating the glioblastoma microenvironment into engineered experimental models. Future Sci OA. 2017;3(3):Fso189. doi:10.4155/fsoa-2016-009428883992
   PubMedGoogle Scholar
• Shah SR, Tippens ND, Park J, et al. YAP controls cell migration and invasion through a Rho-GTPase switch. bioRxiv. 2019;602052.
   Google Scholar
• Park J, Kim D-H, Shah SR, et al. Switch-like enhancement of epithelial-mesenchymal transition by YAP through feedback regulation of WT1 and Rho-family GTPases. Nat Commun. 2019;10(1):2797. doi:10.1038/s41467-019-10729-531243273
   PubMedGoogle Scholar
• Shah SR, David JM, Tippens ND, et al. Brachyury-YAP regulatory axis drives stemness and growth in cancer. Cell Rep. 2017;21(2):495–507. doi:10.1016/j.celrep.2017.09.05729020634
   PubMed Web of Science ®Google Scholar
• Noch EK, Ramakrishna R, Magge R. Challenges in the treatment of glioblastoma: multisystem mechanisms of therapeutic resistance. World Neurosurg. 2018;116:505–517. doi:10.1016/j.wneu.2018.04.02230049045
   PubMedGoogle Scholar
• Jiapaer S, Furuta T, Tanaka S, Kitabayashi T, Nakada M. Potential strategies overcoming the temozolomide resistance for glioblastoma. Neurol Med Chir (Tokyo). 2018;58(10):405–421. doi:10.2176/nmc.ra.2018-014130249919
   PubMed Web of Science ®Google Scholar
• Karlsson J, Vaughan HJ, Green JJ. Biodegradable polymeric nanoparticles for therapeutic cancer treatments. Annu Rev Chem Biomol Eng. 2018;9:105–127. doi:10.1146/annurev-chembioeng-060817-08405529579402
   PubMed Web of Science ®Google Scholar
• Singh R, Lillard JW Jr. Nanoparticle-based targeted drug delivery. Exp Mol Pathol. 2009;86(3):215–223. doi:10.1016/j.yexmp.2008.12.00419186176
   PubMed Web of Science ®Google Scholar
• Martinez Rivas CJ, Tarhini M, Badri W, et al. Nanoprecipitation process: from encapsulation to drug delivery. Int J Pharm. 2017;532(1):66–81. doi:10.1016/j.ijpharm.2017.08.06428801107
   PubMed Web of Science ®Google Scholar
• Barua S, Yoo JW, Kolhar P, Wakankar A, Gokarn YR, Mitragotri S. Particle shape enhances specificity of antibody-displaying nanoparticles. Proc Natl Acad Sci U S A. 2013;110(9):3270–3275. doi:10.1073/pnas.121689311023401509
   PubMed Web of Science ®Google Scholar
• Meyer RA, Mathew MP, Ben-Akiva E, et al. Anisotropic biodegradable lipid coated particles for spatially dynamic protein presentation. Acta Biomater. 2018;72:228–238. doi:10.1016/j.actbio.2018.03.05629631048
   PubMedGoogle Scholar
• Kalaydina RV, Bajwa K, Qorri B, Decarlo A, Szewczuk MR. Recent advances in “smart” delivery systems for extended drug release in cancer therapy. Int J Nanomedicine. 2018;13:4727–4745. doi:10.2147/IJN.S16805330154657
   PubMed Web of Science ®Google Scholar
• Shah SR, Kim J, Schiapparelli P, et al. Verteporfin-loaded polymeric microparticles for intratumoral treatment of brain cancer. Mol Pharm. 2019;16(4):1433–1443. doi:10.1021/acs.molpharmaceut.8b0095930803231
   PubMedGoogle Scholar
• Scott LJ, Goa KL. Verteporfin. Drugs Aging. 2000;16(2):139–146; discussion 147–138. doi:10.2165/00002512-200016020-00005
   Web of Science ®Google Scholar
• Youssef PN, Sheibani N, Albert DM. Retinal light toxicity. Eye (Lond). 2011;25(1):1–14. doi:10.1038/eye.2010.14921178995
   PubMed Web of Science ®Google Scholar
• Liu-Chittenden Y, Huang B, Shim JS, et al. Genetic and pharmacological disruption of the TEAD-YAP complex suppresses the oncogenic activity of YAP. Genes Dev. 2012;26(12):1300–1305. doi:10.1101/gad.192856.11222677547
   PubMed Web of Science ®Google Scholar
• Zanconato F, Cordenonsi M, Piccolo S. YAP/TAZ at the roots of cancer. Cancer Cell. 2016;29(6):783–803. doi:10.1016/j.ccell.2016.05.00527300434
   PubMed Web of Science ®Google Scholar
• Lin C, Hu Z, Lei B, et al. Overexpression of Yes-associated protein and its association with clinicopathological features of hepatocellular carcinoma: a meta-analysis. Liver Transpl. 2017;37(11):1675–1681. doi:10.1111/liv.2017.37.issue-11
   Google Scholar
• Shah SR, Tippens N, Park J, et al. 217 YAP is ready to rac and rho: elucidation of a novel YAP-driven network that potentiates brain cancer cell dispersal and confers poor survival in patients. Neurosurgery. 2016;63(CN_suppl_1):185. doi:10.1227/01.neu.0000489786.22041.2d
   Google Scholar
• Wei H, Wang F, Wang Y, et al. Verteporfin suppresses cell survival, angiogenesis and vasculogenic mimicry of pancreatic ductal adenocarcinoma via disrupting the YAP-TEAD complex. Cancer Sci. 2017;108(3):478–487. doi:10.1111/cas.1313828002618
   PubMedGoogle Scholar
• Huggett MT, Jermyn M, Gillams A, et al. Phase I/II study of verteporfin photodynamic therapy in locally advanced pancreatic cancer. Br J Cancer. 2014;110(7):1698–1704. doi:10.1038/bjc.2014.9524569464
   PubMedGoogle Scholar
• Kim J, Shamul JG, Shah SR, et al. Verteporfin-loaded poly(ethylene glycol)-poly(beta-amino ester)-poly(ethylene glycol) triblock micelles for cancer therapy. Biomacromolecules. 2018;19(8):3361–3370. doi:10.1021/acs.biomac.8b0064029940101
   PubMedGoogle Scholar
• Martinez-Gutierrez JC, Ruiz-Valls A, Shah SR, Riggins GJ, Quinones-Hinojosa A. MNGO-08: meningioma growth inhibition and radiosensitization by the small molecule yap inhibitor verteporfin. Neuro Oncol. 2015;17(Suppl 5):v131–v131. doi:10.1093/neuonc/nov220.08
   Google Scholar
• Green JJ, Langer R, Anderson DG. A combinatorial polymer library approach yields insight into nonviral gene delivery. Acc Chem Res. 2008;41(6):749–759. doi:10.1021/ar700233618507402
   PubMed Web of Science ®Google Scholar
• Sunshine JC, Peng DY, Green JJ. Uptake and transfection with polymeric nanoparticles are dependent on polymer end-group structure, but largely independent of nanoparticle physical and chemical properties. Mol Pharm. 2012;9(11):3375–3383. doi:10.1021/mp300417622970908
   PubMedGoogle Scholar
• Kim J, Kang Y, Tzeng SY, Green JJ. Synthesis and application of poly(ethylene glycol)-co-poly(beta-amino ester) copolymers for small cell lung cancer gene therapy. Acta Biomater. 2016;41:293–301. doi:10.1016/j.actbio.2016.05.04027262740
   PubMed Web of Science ®Google Scholar
• Galli R, Binda E, Orfanelli U, et al. Isolation and characterization of tumorigenic, stem-like neural precursors from human glioblastoma. Cancer Res. 2004;64(19):7011–7021. doi:10.1158/0008-5472.CAN-04-136415466194
   PubMed Web of Science ®Google Scholar
• Tzeng SY, Wilson DR, Hansen SK, Quinones-Hinojosa A, Green JJ. Polymeric nanoparticle-based delivery of TRAIL DNA for cancer-specific killing. Bioeng Transl Med. 2016;1(2):149–159. doi:10.1002/btm2.1001928349127
   PubMedGoogle Scholar
• Israelachvili J. The science and applications of emulsions — an overview. Colloids Surf a Physicochem Eng Asp. 1994;91:1–8. doi:10.1016/0927-7757(94)02743-9
   Web of Science ®Google Scholar
• Tzeng SY, Green JJ. Subtle changes to polymer structure and degradation mechanism enable highly effective nanoparticles for siRNA and DNA delivery to human brain cancer. Adv Healthc Mater. 2013;2(3):468–480. doi:10.1002/adhm.v2.323184674
   PubMed Web of Science ®Google Scholar
• Qiu L, Xu C-R, Zhong F, Hong C-Y, Pan C-Y. Fabrication of functional nano-objects through raft dispersion polymerization and influences of morphology on drug delivery. ACS Appl Mater Interfaces. 2016;8(28):18347–18359. doi:10.1021/acsami.6b0469327399846
   PubMedGoogle Scholar
• Park JH, von Maltzahn G, Zhang L, et al. Systematic surface engineering of magnetic nanoworms for in vivo tumor targeting. Small. 2009;5(6):694–700. doi:10.1002/smll.20080178919263431
   PubMed Web of Science ®Google Scholar
• Park JH, von Maltzahn G, Zhang L, et al. Magnetic iron oxide nanoworms for tumor targeting and imaging. Adv Mater. 2008;20(9):1630–1635. doi:10.1002/adma.20080000421687830
   PubMed Web of Science ®Google Scholar
• Toy R, Peiris PM, Ghaghada KB, Karathanasis E. Shaping cancer nanomedicine: the effect of particle shape on the in vivo journey of nanoparticles. Nanomedicine (Lond). 2014;9(1):121–134. doi:10.2217/nnm.13.19124354814
   PubMed Web of Science ®Google Scholar
• Meng F, Engbers GH, Feijen J. Polyethylene glycol-grafted polystyrene particles. J Biomed Mater Res A. 2004;70(1):49–58. doi:10.1002/jbm.a.3005615174108
   PubMedGoogle Scholar
• Wang X, Hu X, Li J, et al. Influence of cell size on cellular uptake of gold nanoparticles. Biomater Sci. 2016;4(6):970–978. doi:10.1039/C6BM00171H27095054
   PubMedGoogle Scholar
• Farvadi F, Ghahremani MH, Hashemi F, et al. Cell shape affects nanoparticle uptake and toxicity: an overlooked factor at the nanobio interfaces. J Colloid Interface Sci. 2018;531:245–252. doi:10.1016/j.jcis.2018.07.01330032011
   PubMedGoogle Scholar
• Hatoum A, Mohammed R, Zakieh O. The unique invasiveness of glioblastoma and possible drug targets on extracellular matrix. Cancer Manag Res. 2019;11:1843–1855. doi:10.2147/CMAR.S18614230881112
   PubMed Web of Science ®Google Scholar
• Brandao M, Simon T, Critchley G, Giamas G. Astrocytes, the rising stars of the glioblastoma microenvironment. Glia. 2019;67(5):779–790. doi:10.1002/glia.v67.530240060
   PubMedGoogle Scholar
• Merzak A, Koocheckpour S, Pilkington GJ. CD44 mediates human glioma cell adhesion and invasion in vitro. Cancer Res. 1994;54(15):3988–3992.7518347
   PubMed Web of Science ®Google Scholar
• Nam L, Coll C, Erthal LCS, et al. Drug delivery nanosystems for the localized treatment of glioblastoma multiforme. Materials. 2018;11(5):779. doi:10.3390/ma11050779
   PubMed Web of Science ®Google Scholar